Evidence map›Paper›PMID 35935261›Full record

ArticleAsia-Pacific journal of oncology nursing2022

Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy.

Guolong Zhang, Huiwen Weng, Yinghong Li, Pingdong Li, Yucui Gong, Jieya Chen, Lin Wei, Linghui Zeng, Yingchun Zeng, Andy Sk Cheng

Abstract read
In one paragraph

Article in Asia-Pacific journal of oncology nursing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Symptom clusters and symptom network analysis during immunotherapy in lung cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guolong ZhangSchool of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, China.
Huiwen WengSchool of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yinghong LiDepartment of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Pingdong LiDepartment of Nursing, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yucui GongDepartment of Nursing, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jieya ChenDepartment of Nursing, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Lin WeiDepartment of Nursing, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Linghui ZengSchool of Medicine, Zhejiang University City College, Hangzhou, China.
Yingchun ZengSchool of Medicine, Zhejiang University City College, Hangzhou, China.
Andy Sk ChengDepartment of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aims of this study were to examine the symptom severity and interference among patients with lung cancer treated with PD-1 immunotherapy, explore whether those symptoms were clustered together, and identify factors associated with symptom clusters. Methods: A cross-sectional study was conducted. Data were collected by demographic and clinical characteristic questionnaires and the M.D. Anderson Symptom Inventory Lung Cancer Module. Symptom clusters were identified using exploratory factor analysis, and stepwise linear regression was applied to analyze the factors affecting the symptom clusters. Results: A total of 148 patients with lung cancer treated with PD-1 immunotherapy participated in this study. The overall symptom burdens of these patients were mainly at a mild level. The patient symptom clusters identified in this study were a general cluster, a treatment-related cluster, a pulmonary cluster, a gastrointestinal cluster, and a neural cluster. The patients' Karnofsky performance status (KPS) score ( Conclusions: The symptom burdens of patients with lung cancer and treated with PD-1 immunotherapy were at a mild level and appeared to be clustered. In addition, because the symptoms that comprise a cluster are interrelated, the diagnosis and management of each symptom in a cluster should not be performed in isolation, and each symptom in a cluster should be treated either simultaneously or in an orderly manner.

Indexed as

Lung cancerprogrammed death-1 immunotherapysymptom cluster

Identifiers

PMID35935261
PMCPMC9345784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.